Your browser is no longer supported. Please, upgrade your browser.
CRSP CRISPR Therapeutics AG daily Stock Chart
CRISPR Therapeutics AG
Index- P/E- EPS (ttm)-1.63 Insider Own3.10% Shs Outstand46.09M Perf Week-11.20%
Market Cap2.69B Forward P/E- EPS next Y-2.92 Insider Trans-50.19% Shs Float27.29M Perf Month-10.59%
Income-68.90M PEG- EPS next Q-0.63 Inst Own42.10% Short Float12.37% Perf Quarter7.92%
Sales39.70M P/S67.74 EPS this Y18.10% Inst Trans1.89% Short Ratio2.16 Perf Half Y96.27%
Book/sh6.33 P/B9.22 EPS next Y-13.20% ROA-24.40% Target Price67.07 Perf Year252.99%
Cash/sh7.42 P/C7.87 EPS next 5Y- ROE-35.20% 52W Range16.15 - 73.90 Perf YTD148.51%
Dividend- P/FCF- EPS past 5Y- ROI-32.00% 52W High-21.04% Beta-
Dividend %- Quick Ratio24.40 Sales past 5Y- Gross Margin- 52W Low261.30% ATR3.65
Employees127 Current Ratio24.40 Sales Q/Q-48.10% Oper. Margin- RSI (14)42.40 Volatility7.27% 5.97%
OptionableYes Debt/Eq0.00 EPS Q/Q-14.10% Profit Margin- Rel Volume0.44 Prev Close58.39
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.56M Price58.35
Recom2.30 SMA20-5.63% SMA50-6.83% SMA20043.23% Volume687,214 Change-0.07%
May-15-18Reiterated Chardan Capital Markets Buy $25 → $72.50
Apr-06-18Initiated Goldman Buy $86
Mar-08-18Initiated JMP Securities Mkt Outperform $69
Jan-23-18Upgrade SunTrust Hold → Buy
Dec-22-17Initiated Piper Jaffray Overweight
Jul-14-17Initiated SunTrust Hold $16
Mar-28-17Initiated Chardan Capital Markets Buy $23.50
Jul-17-18 03:01PM  Yet Another CRISPR Worry: What Should Investors Do? Motley Fool
08:10AM  Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Tonix Pharmaceuticals ACCESSWIRE
Jul-16-18 07:31PM  [$$] New Research Prompts Selloff in Companies Using Crispr Technology The Wall Street Journal -8.60%
03:16PM  A Single Study Is No Reason to Sell Crispr Stock InvestorPlace
02:28PM  CRISPR gene editing can cause risky collateral DNA damage - study Reuters
01:05PM  CRISPR Therapeutics Stock History: The Rise of the World's Biggest Gene-Editing Biotech Motley Fool
12:21PM  Gene-editing stocks tumble on concerns about DNA damage MarketWatch
Jul-10-18 09:37AM  Here's Why CRISPR Stocks Have Gained as Much as 169% in 2018 (So Far) Motley Fool
Jul-09-18 01:26PM  Here's Why CRISPR Therapeutics AG Fell 14.7% in June Motley Fool
02:00AM  Abingworth Raises $315m for ABV VII 12th Life Sciences Fund PR Newswire
Jul-08-18 03:15PM  Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far Motley Fool
Jul-06-18 09:03AM  Are Options Traders Betting on a Big Move in CRISPR Therapeutics (CRSP) Stock? Zacks
Jul-05-18 08:39AM  Nightstar Therapeutics (NITE) in Focus: Stock Moves 6.3% Higher Zacks
Jul-03-18 11:05PM  A Deep Dive Into The Latest CRISPR Controversy: Heres What You Should Know Motley Fool
Jul-02-18 10:34AM  Jazz Sells Pain Drug Prialt's Rights to TerSera Therapeutics Zacks
Jul-01-18 10:02AM  The 2 Most Wildly Overvalued Biotech Stocks Right Now Motley Fool
Jun-29-18 11:24AM  Pfizer's Leukemia Candidate Gets Priority Review From FDA Zacks
Jun-27-18 11:32AM  Agios Out-Licenses China Rights to Leukemia Drug Tibsovo Zacks -6.27%
08:00AM  Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Incyte ACCESSWIRE
Jun-25-18 07:05AM  Today's Free Research Reports Coverage on CorMedix and Three More Biotech Stocks ACCESSWIRE
Jun-22-18 07:07PM  Cramer's lightning round: I don't like Snap's ownership s... CNBC Videos
03:12PM  Editas Medicine Stock History: The Story Behind the CRISPR Gene-Editing Pioneer Motley Fool
09:36AM  Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia Zacks
Jun-21-18 08:10PM  Knowledge, Certainty, and Destiny: How to Keep Up With Science & Technology Zacks
10:35AM  Paratek's Antibiotic Candidate Gets FDA Committee Date Zacks
08:07AM  3 Soaring Biotech Stocks. Can They Keep Climbing? Motley Fool
Jun-20-18 06:06PM  CRISPR Science and Stocks: Knowing Enough to Invest Zacks +5.16%
11:30AM  2 High-Flying Biotech Stocks With Even More Room to Grow Motley Fool
10:08AM  Amgen Gets EU Nod to Add Survival Data on Blincyto's Label Zacks
Jun-19-18 09:05AM  CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing GlobeNewswire
08:20AM  Today's Research Reports on Trending Tickers: Corcept Therapeutics and CRISPR Therapeutics ACCESSWIRE
Jun-18-18 02:22PM  Is Gene Editing Dangerous? 4 Things You Should Know Motley Fool +5.60%
02:08PM  Top Stock Picks for the Week of June 18, 2018 Zacks
Jun-16-18 12:01AM  [$$] Gene-Editing Selloff Is Overdone
Jun-15-18 10:52AM  BioMarin Begins Pediatric Study on Achondroplasia Candidate Zacks
Jun-13-18 10:28AM  Idera Stock Down, Study on Dermatomyositis Candidate Fails Zacks
08:01AM  Should CRISPR Stock Investors Worry About Cancer? Motley Fool
06:02AM  CRISPR Could Cause Cancer? Here Are 3 Reasons Investors Shouldn't Panic Motley Fool
Jun-12-18 11:23AM  Galmed's 200% Jump Leads Biotechs Higher
08:10AM  Todays Research Reports on Stocks to Watch: CRISPR Therapeutics and Cardiome Pharma ACCESSWIRE
07:01AM  CRISPR-related stocks sink after report that gene-editing technology might cause cancer MarketWatch
Jun-11-18 04:57PM  Here's Why CRISPR Stocks are Getting Rocked Today Motley Fool -12.59%
04:34PM  Why Adient, CRISPR Therapeutics, and Applied Optoelectronics Slumped Today Motley Fool
01:56PM  CRISPR stocks tank after research shows edited cells might cause cancer CNBC
12:03PM  CRISPR Therapeutics' stock tumbles after report that edited genes might seed tumors MarketWatch
10:31AM  2 Cheap Growth Stocks to Buy Right Now Motley Fool
12:50AM  [$$] Gene editing companies hit by reports that say technique could raise cancer risk Financial Times
Jun-08-18 04:05PM  Here's Why the Top CRISPR Stocks Rose as Much as 47.1% in May Motley Fool
03:31AM  FDA Creates Potential Buying Opportunity for CRSP Investopedia
Jun-05-18 12:04PM  Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason InvestorPlace
08:00AM  CRISPR Therapeutics to Participate in Three June Conferences GlobeNewswire
06:33AM  Buy These 2 Biotech Stocks on the Dip After an FDA Delay Motley Fool
12:21AM  After Soaring to New Highs, Crispr Therapeutics AG Stock Ripe for a Fall InvestorPlace
Jun-02-18 09:14AM  CRISPR Therapeutics AG (NASDAQ:CRSP): Does The Earnings Decline Make It An Underperformer? Simply Wall St.
Jun-01-18 08:41AM  Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex Zacks
May-31-18 04:43PM  Why Analysts Remain Bullish Despite Holdup For Crispr Gene-Editing Tech Investor's Business Daily -6.36%
03:10PM  Should You Buy the Dip in CRISPR Therapeutics? Zacks
11:45AM  3 Possible Outcomes From The Clinical Hold On Crispr Therapeutics's Sickle Cell Candidate Benzinga
11:23AM  5 Biotech Stocks to Boost Your Portfolios Health This Year InvestorPlace
11:10AM  5 Top Performing Stocks of the Best ETF of May Zacks
10:09AM  Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA Zacks
08:31AM  4 Reasons Not to Worry About Crispr Therapeutics AG's Latest Setback Motley Fool
08:20AM  Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Editas Medicine ACCESSWIRE
08:04AM  5 Biotech Stocks to Boost Your Portfolio's Health This Year Zacks
07:55AM  Is Crispr Therapeutics Stock a Bad News Buy? Motley Fool
07:02AM  Dow Jones Futures: Hot Biotech Dives On FDA; 3 Breakout Bids With Flaws Investor's Business Daily
May-30-18 08:19PM  CRISPR, Vertex say FDA puts brakes on upcoming gene editing trial American City Business Journals +6.79%
04:51PM  FDA places clinical hold on drug CNBC Videos
04:46PM  Gene-Therapy Company Crispr Drops as FDA Puts Trial on Hold Bloomberg
04:30PM  CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease GlobeNewswire
03:44PM  After-hours buzz: CRSP, BOX & more CNBC
03:37PM  What Makes This CRISPR Stock Better Than the Rest? Motley Fool
May-24-18 04:23PM  Is Genome Editing the Next Biotech Breakthrough? Zacks
08:10AM  Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Align Technology ACCESSWIRE
May-23-18 03:13PM  3 Stocks That Feel Like Netflix in 2002 Motley Fool +9.11%
May-21-18 07:05PM  Cramer's lightning round: The bears are wrong about cruis... CNBC Videos
May-19-18 07:17AM  3 Healthcare Stocks That Soared This Week: Are They Buys? Motley Fool
May-16-18 02:37PM  MARKETS: Russell 2000 hits all-time high; Walmart earnings on deck; oil prices reverse; healthcare stocks in focus Yahoo Finance Video
07:00AM  CRISPR Stocks Deserve a Second Look. Here's Why. Investopedia
May-15-18 08:00AM  CRISPR Therapeutics Announces Presentations at the ASGCT 21st Annual Meeting GlobeNewswire
06:33AM  These 3 Stocks Have Doubled Investors' Money Motley Fool
May-11-18 07:20PM  Your Guide to Investing in Gene Editing Motley Fool
May-09-18 09:07AM  Is CRISPR Therapeutics AGs (NASDAQ:CRSP) Liquidity Good Enough? Simply Wall St.
May-08-18 05:45PM  5 Biotech Stocks Set to Beat Estimates This Earnings Season Zacks
08:00AM  CRISPR Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results GlobeNewswire
May-03-18 04:01PM  CRISPR Therapeutics to Participate in May Investor Conferences GlobeNewswire
May-02-18 12:19PM  What Diseases Could Gene Editing Cure? Motley Fool
11:23AM  Don't Waste Your Money on Bitcoin, These 3 Stocks Are Better Buys Motley Fool
May-01-18 04:56PM  Top Gene-Editing Stocks for Long-Term Investors Motley Fool
Apr-30-18 08:20AM  Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Merck & Co. ACCESSWIRE
Apr-29-18 06:32AM  5 Things You'll Want to Know From Vertex Pharmaceuticals' Q1 Conference Call Motley Fool
Apr-27-18 02:35PM  Exclusive: Gene editing pioneer Feng Zhang launches new startup in Cambridge American City Business Journals
Apr-23-18 10:00AM  Geron Corporation: The Clock Is Ticking Motley Fool -8.27%
06:34AM  What Are Analysts Expecting From CRISPR Therapeutics AG (NASDAQ:CRSP) Over The Next Few Years? Simply Wall St.
Apr-20-18 05:12PM  Big Week in Tech for Amazon, Alphabet and Microsoft Yahoo Finance Video -5.83%
Apr-16-18 04:01PM  CRISPR Therapeutics Presents Positive Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018 GlobeNewswire
Apr-13-18 08:00AM  CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018 GlobeNewswire
Apr-12-18 08:25AM  Market Trends Toward New Normal in Argo Group International, Methanex, Industrias Bachoco, S.A. de C.V, CRISPR Therapeutics AG, Astec Industries, and Sprague Resources LP Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire +5.52%
Apr-04-18 04:01PM  CRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory Affairs GlobeNewswire
Apr-03-18 09:32AM  Oops! CRISPR Concerns Turn Out to be a Big Nothingburger Motley Fool
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; and Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CELGENE CORP /DE/10% OwnerNov 21Sale19.2580,0001,540,0004,173,019Dec 07 09:57 AM
CAGNONI PABLO JDirectorJul 05Option Exercise5.591,6849,4141,684Jul 05 06:25 PM
CAGNONI PABLO JDirectorJul 05Sale62.001,684104,4080Jul 05 06:25 PM
CAGNONI PABLO JDirectorJul 03Option Exercise5.595,81632,5115,816Jul 05 06:25 PM
CAGNONI PABLO JDirectorJul 03Sale62.005,816360,5920Jul 05 06:25 PM
EMSTER KURT VONDirectorJun 05Sale12.5192011,50918,316Jun 07 04:36 PM
Kulkarni SamarthChief Executive OfficerJun 01Option Exercise1.8115,00027,150163,560Jun 05 08:20 PM
Kulkarni SamarthChief Executive OfficerJun 01Sale69.3615,0001,040,400148,560Jun 05 08:20 PM
Novak RodgerPresidentMay 17Option Exercise8.2775,000620,4241,223,007May 21 04:54 PM
Novak RodgerPresidentMay 17Sale60.0075,0004,500,0001,148,007May 21 04:54 PM
Bolzon Bradley J PhDDirectorMay 15Sale57.9944,0002,551,440640,014May 17 05:15 PM
Woiwode ThomasDirectorMay 15Sale57.9944,0002,551,440640,014May 17 05:11 PM
EMSTER KURT VONDirectorMay 14Sale55.36400,00022,142,5561,237,202May 15 08:04 PM
EMSTER KURT VONDirectorMay 11Sale52.84250,00013,209,9001,637,202May 15 08:04 PM
Bolzon Bradley J PhDDirectorMay 08Sale50.549,241467,06734,745May 09 05:14 PM
Woiwode ThomasDirectorMay 08Sale51.451,65385,0475,629May 09 05:15 PM
Bolzon Bradley J PhDDirectorMay 07Sale50.38119,7096,030,82634,977May 09 05:14 PM
Woiwode ThomasDirectorMay 07Sale50.38119,7096,030,82634,977May 09 05:15 PM
Bolzon Bradley J PhDDirectorApr 30Sale50.2930,5661,537,13838,064May 02 06:00 PM
Woiwode ThomasDirectorApr 30Sale50.2930,5661,537,13838,064May 02 06:00 PM
Bolzon Bradley J PhDDirectorApr 27Sale50.0211,648582,65538,852Apr 30 08:58 PM
Woiwode ThomasDirectorApr 27Sale50.0211,648582,65538,852Apr 30 08:57 PM
Bolzon Bradley J PhDDirectorApr 26Sale50.11210,61010,553,78239,152Apr 30 08:58 PM
Woiwode ThomasDirectorApr 26Sale50.11210,61010,553,78239,152Apr 30 08:57 PM
Woiwode ThomasDirectorApr 24Sale50.9922,8411,164,65544,582Apr 26 05:01 PM
Bolzon Bradley J PhDDirectorApr 24Sale50.9922,8411,164,65544,582Apr 26 04:57 PM
Versant Venture Capital V, L.P10% OwnerApr 24Sale50.9922,8411,164,65544,582Apr 26 04:44 PM
Versant Venture Capital IV, L.10% OwnerApr 23Sale50.68101,9945,168,90145,171Apr 24 07:44 PM
Woiwode ThomasDirectorApr 23Sale50.68101,9945,168,90145,171Apr 24 07:42 PM
Bolzon Bradley J PhDDirectorApr 23Sale50.68101,9945,168,90145,171Apr 24 07:41 PM
Dylan-Hyde TylerChief Legal OfficerJan 16Option Exercise12.5721,000263,97045,094Jan 18 05:38 PM
Dylan-Hyde TylerChief Legal OfficerJan 16Sale28.0366,0001,850,25525,204Jan 18 05:38 PM
EMSTER KURT VONDirectorJan 05Buy22.7565,9341,499,9991,887,202Jan 11 09:00 PM
BAYER AKTIENGESELLSCHAFT10% OwnerJan 05Buy22.75527,47211,999,9885,632,802Jan 30 02:21 PM
EMSTER KURT VONDirectorJan 05Sale26.9692,3372,489,4061,821,268Jan 09 04:39 PM
Dylan-Hyde TylerChief Legal OfficerJan 02Option Exercise12.578,000100,56078,204Jan 04 07:14 PM
EMSTER KURT VONDirectorJan 02Sale26.7637,7541,010,1231,913,605Jan 04 05:29 PM
Dylan-Hyde TylerChief Legal OfficerJan 02Sale21.6438,000822,50070,204Jan 04 07:14 PM
Dylan-Hyde TylerChief Legal OfficerDec 29Option Exercise13.3315,300203,909124,274Jan 02 04:18 PM
Dylan-Hyde TylerChief Legal OfficerDec 29Sale22.7430,300689,055100,204Jan 02 04:18 PM
Dylan-Hyde TylerChief Legal OfficerDec 28Option Exercise14.4370010,101115,904Jan 02 04:18 PM
Dylan-Hyde TylerChief Legal OfficerDec 28Sale21.7570015,225115,204Jan 02 04:18 PM
Bolzon Bradley J PhDDirectorDec 22Sale20.3026,016528,23727,724Dec 27 04:17 PM
Dylan-Hyde TylerChief Legal OfficerDec 22Sale20.5515,000308,250115,204Dec 27 04:17 PM
Woiwode ThomasDirectorDec 22Sale20.293,05962,0704,959Dec 27 04:14 PM
Kulkarni SamarthChief Executive OfficerDec 21Option Exercise1.8115,00027,150148,560Dec 26 05:11 PM
Dylan-Hyde TylerChief Legal OfficerDec 15Sale18.9015,000283,496130,204Dec 19 04:10 PM
CELGENE CORP /DE/10% OwnerDec 04Sale19.4730,485593,5433,722,534Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerDec 01Sale19.1087,9911,680,6283,753,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 30Sale19.0412,666241,1613,841,010Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 29Sale19.254,26382,0633,853,676Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 28Sale19.225,08097,6383,857,939Dec 07 09:57 AM
Woiwode ThomasDirectorNov 27Sale20.242004,0488,018Nov 28 04:11 PM
Bolzon Bradley J PhDDirectorNov 27Sale20.242004,04853,740Nov 28 04:10 PM
CELGENE CORP /DE/10% OwnerNov 27Sale19.7527,990552,8033,863,019Dec 07 09:57 AM
Woiwode ThomasDirectorNov 24Sale20.211,70034,3588,218Nov 28 04:11 PM
Bolzon Bradley J PhDDirectorNov 24Sale20.211,50730,45053,940Nov 28 04:10 PM
CELGENE CORP /DE/10% OwnerNov 24Sale20.0026,010520,2003,891,009Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 22Sale19.76256,0005,058,5603,917,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 20Sale19.02158,7183,018,8164,253,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 17Sale18.4451,282945,6404,411,737Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 16Sale18.39105,0001,930,9504,463,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 15Sale17.6715,000265,0504,568,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 14Sale17.1914,907256,2514,583,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 13Sale17.7665,0931,156,0524,597,926Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 10Sale17.2810,000172,8004,663,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 09Sale17.0820,000341,6004,673,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 08Sale18.0616,875304,7634,693,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 07Sale18.5423,000426,4204,709,894Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 06Sale18.8979,3271,498,4874,732,894Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 03Sale19.1022,759434,6974,812,221Dec 07 09:57 AM
Novak RodgerChief Executive OfficerSep 05Option Exercise1.813,8536,9741,151,860Sep 05 06:33 PM
Novak RodgerChief Executive OfficerSep 05Sale20.333,85378,3201,148,007Sep 05 06:33 PM
Novak RodgerChief Executive OfficerAug 31Sale20.8714,617305,0731,148,007Sep 05 06:33 PM